JASPER THERAPEUTICS, INC. Research and Development Expense
JASPER THERAPEUTICS, INC. (JSPR) reported Research and Development Expense of $5.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- JASPER THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $5.13M, a 75.77% decline year-over-year.
- JASPER THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $5.81M, a 64.02% decline year-over-year.
- JASPER THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $11.36M, a 42.55% decline year-over-year.
- JASPER THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $14.39M, a 0.44% decline year-over-year.
- JASPER THERAPEUTICS, INC. research and development expense for fiscal 2025 was $63.10M, a 13.05% increase from fiscal 2024.
- JASPER THERAPEUTICS, INC. research and development expense for fiscal 2024 was $55.82M, a 7.79% increase from fiscal 2023.
- JASPER THERAPEUTICS, INC. research and development expense for fiscal 2023 was $51.78M, a 49.55% increase from fiscal 2022.
- JASPER THERAPEUTICS, INC. research and development expense for fiscal 2022 was $34.63M, a 36.21% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.13M 10-Q · filed 2026-08-14 | $10.95M 10-Q · filed 2026-08-14 | $22.31M derived: sum of 3 quarters · filed 2026-08-14 | $36.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.81M 10-Q · filed 2026-05-14 | $17.17M derived: sum of 2 quarters · filed 2026-05-14 | $31.57M derived: sum of 3 quarters · filed 2026-05-14 | $52.76M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $11.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $25.75M derived: sum of 2 quarters · filed 2026-03-30 | $46.95M derived: sum of 3 quarters · filed 2026-08-14 | $63.10M 10-K · filed 2026-03-30 |
| 2025-09-30 | $14.39M 10-Q · filed 2025-11-10 | $35.59M derived: sum of 2 quarters · filed 2026-08-14 | $51.74M 10-Q · filed 2025-11-10 | $71.52M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $21.20M 10-Q · filed 2026-08-14 | $37.35M 10-Q · filed 2026-08-14 | $57.13M derived: sum of 3 quarters · filed 2026-08-14 | $71.58M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $16.16M 10-Q · filed 2026-05-14 | $35.93M derived: sum of 2 quarters · filed 2026-05-14 | $50.38M derived: sum of 3 quarters · filed 2026-05-14 | $61.68M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $19.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $34.23M derived: sum of 2 quarters · filed 2026-03-30 | $45.52M derived: sum of 3 quarters · filed 2026-03-30 | $55.82M 10-K · filed 2026-03-30 |
| 2024-09-30 | $14.46M 10-Q · filed 2025-11-10 | $25.75M derived: sum of 2 quarters · filed 2025-11-10 | $36.05M 10-Q · filed 2025-11-10 | $49.88M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $11.30M 10-Q · filed 2025-08-13 | $21.59M 10-Q · filed 2025-08-13 | $35.43M derived: sum of 3 quarters · filed 2025-08-13 | $50.28M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $10.30M 10-Q · filed 2025-05-12 | $24.13M derived: sum of 2 quarters · filed 2025-05-12 | $38.98M derived: sum of 3 quarters · filed 2025-05-12 | $52.28M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $13.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $28.68M derived: sum of 2 quarters · filed 2025-02-28 | $41.98M derived: sum of 3 quarters · filed 2025-02-28 | $51.78M 10-K · filed 2025-02-28 |
| 2023-09-30 | $14.85M 10-Q · filed 2024-11-07 | $28.14M derived: sum of 2 quarters · filed 2024-11-07 | $37.95M 10-Q · filed 2024-11-07 | $47.23M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $13.30M 10-Q · filed 2024-08-13 | $23.10M 10-Q · filed 2024-08-13 | $32.38M derived: sum of 3 quarters · filed 2024-08-13 | $41.41M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $9.80M 10-Q · filed 2024-05-14 | $19.09M derived: sum of 2 quarters · filed 2024-05-14 | $28.11M derived: sum of 3 quarters · filed 2024-05-14 | $36.24M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $9.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $18.30M derived: sum of 2 quarters · filed 2024-03-05 | $26.44M derived: sum of 3 quarters · filed 2024-03-05 | $34.63M 10-K · filed 2024-03-05 |
| 2022-09-30 | $9.02M 10-Q · filed 2023-11-09 | $17.16M derived: sum of 2 quarters · filed 2023-11-09 | $25.34M 10-Q · filed 2023-11-09 | $34.00M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $8.13M 10-Q · filed 2023-08-11 | $16.32M 10-Q · filed 2023-08-11 | $24.98M derived: sum of 3 quarters · filed 2023-08-11 | $32.17M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $8.19M 10-Q · filed 2023-05-12 | $16.84M derived: sum of 2 quarters · filed 2023-05-12 | $24.03M derived: sum of 3 quarters · filed 2023-05-12 | $29.19M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $8.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $15.85M derived: sum of 2 quarters · filed 2023-03-08 | $21.00M derived: sum of 3 quarters · filed 2023-03-08 | $25.42M 10-K · filed 2023-03-08 |
| 2021-09-30 | $7.19M 10-Q · filed 2022-11-10 | $12.34M derived: sum of 2 quarters · filed 2022-11-10 | $16.76M 10-Q · filed 2022-11-10 | $21.41M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $5.16M 10-Q · filed 2022-08-12 | $9.58M 10-Q · filed 2022-08-12 | $14.22M derived: sum of 3 quarters · filed 2022-08-12 | $18.74M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $4.42M 10-Q · filed 2022-05-12 | $9.07M derived: sum of 2 quarters · filed 2022-05-12 | $13.59M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $9.17M derived: sum of 2 quarters · filed 2022-03-18 | $15.88M 10-K · filed 2022-03-18 | |
| 2020-09-30 | $4.52M 10-Q · filed 2021-11-12 | $11.24M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |